Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OxyMOTION: Intranasal Oxytocin in AVP Deficiency
NCT06676774Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- May 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin nasal spray in arginine vasopressin deficiency (CDI) (4 arms), sponsored by University Hospital Basel. Primary endpoints: Recognition of facial emotions and body expressions up to 4 weeks and Cortisol in response to acute psychosocial stress (TSST) up to 10 weeks. Started May 2025; status: recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
arginine vasopressin deficiency (CDI)
Beyond the preview
Go deeper on NCT06676774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06676774.